ArticleAging medicine (Milton (N.S.W))2025
Visualization of OPN-Targeted Self-Assembled Micelles Encapsulated With an SIRT6 Activator and Doped Indocyanine Green for Attenuating Vascular Aging.
Article in Aging medicine (Milton (N.S.W)), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Sirtuin 6 (SIRT6) is a longevity-associated gene with recognized therapeutic potential for vascular aging through the regulation of vascular smooth muscle cells (VSMCs) senescence. This study aims to develop a visualized nanodelivery system for a SIRT6 activator to attenuate vascular aging in a mouse model. Methods: The expression of the vascular aging marker, osteopontin (OPN), was detected by Western blot and histological staining in the aortas of naturally aging C57BL/6 mice. The SIRT6 activator MDL800 and the near-infrared (NIR) agent indocyanine green (ICG) were encapsulated by poly(caprolactone)-poly(ethylene glycol) (PCL-PEG), which was modified with OPN-targeting peptides, to construct OPN-targeting micelles loaded with MDL800 and ICG (OPN-MI). Particle size and zeta potential were assessed using transmission electron microscopy (TEM) and dynamic light scattering (DLS). The biocompatibility and in vitro NIR signals were evaluated in senescent VSMCs. NIR fluorescence imaging was then performed to visualize the temporal variation and biodistribution of OPN-MI micelles in aging vessels. After 8 weeks of intravenous injection into naturally aging mice, bioinformatics analysis, pulse wave velocity (PWV) measurement, pathological staining, and molecular biological experiments were conducted to explore the anti-aging mechanism of OPN-MI micelles. Results: The expression of OPN in the aortas of naturally aging mice was significantly higher than that in control mice ( Conclusions: The visualized OPN-targeted micelles encapsulating MDL800 and ICG effectively attenuate vascular aging in a naturally aging mouse model. This delivery system holds promise as a therapeutic strategy for delaying vascular aging in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.